Phase 3 AXIS 1032 Trial Discussion with Brian I. Rini, MD

AXIS 1032 is a pivotal Phase 3 clinical trial comparing axitinib to sorafenib in patients with previously-treated advanced renal cell carcinoma (RCC). Axitinib significantly extended progression-free survival, with a median PFS of 6.7 months, compared with 4.7 months for those treated with sorafenib, a standard of care for this patient population.